Lung Cancer

Expert Interviews

Insights on latest treatment developments and implications for clinical practice
Author Interview
Hirohito Tada reports the survival results from the phase 3 IMPACT trial of adjuvant gefitinib versus cisplatin plus vinorelbine in Japanese patients after complete resection of stage II-III non-small-cell lung cancer with an EGFR mutation, and compares the findings with those of the ADJUVANT-CTONG 1104 trial in a similar population of Chinese patients.
Interviewee: Hirohito Tada, MD
Interview Date: June 25, 2021
Subtitles Available: English
Author Interview
Fabrice Barlesi gives an update on an integrated analysis of three trials investigating the use of entrectinib in patients with ROS1 fusion-positive advanced non-small-cell lung cancer, including those with central nervous system metastases
Interviewee: Fabrice Barlesi, MD, PhD
Interview Date: May 18, 2021
Subtitles Available: English
Author Interview
Cardiologist Michael Ewer discusses his review of cardiac safety data for advanced non-small-cell lung cancer patients given the third-generation tyrosine kinase inhibitor osimertinib
Interviewee: Michael Ewer, MD, JD, PhD
Interview Date: February 12, 2021
Subtitles Available: English
Author Interview
ALTA-1L investigator Sanjay Popat discusses the updated findings for the phase 3 trial of brigatinib versus crizotinib for patients with ALK inhibitor-naïve advanced non-small-cell lung cancer.
Interviewee: Sanjay Popat, BSc, PhD, FRCP
Interview Date: November 11, 2020
Subtitles Available: English
New content added regularly, don't miss out!

This site is intended for healthcare professionals in France, Germany, Italy, Japan and the United Kingdom only.

The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.

© 2021 American Society of Clinical Oncology (ASCO®). All Rights Reserved.

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare | Contact Us | Privacy Policy

We'd love your feedback!

Before you go please let us have your feedback...